May 18, 2020
ChemoCentryx on track to check with FDA for Avacopan, in the treatment of ANCA vasculitis
Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx, said that the company will release topline data from the LUMINA-2 study of CCX140.